Suppressor of Tumorigenicity 3 disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

ST3 MCID: SPP010 MIFTS: 50	Suppressor of Tumorigenicity 3 (ST3) Categories: Cancer diseases, Endocrine diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Suppressor of Tumorigenicity 3

MalaCards integrated aliases for Suppressor of Tumorigenicity 3:

Name: Suppressor of Tumorigenicity 3 ⁵⁷ ⁷¹

Cervical Carcinoma ⁵⁷ ¹² ⁵³ ¹⁶

Cervical Carcinoma, Tumor-Suppressor Gene Involved in ⁵⁷

Tumor-Suppressor Gene, Hela Cell Type ⁵⁷

Cervix Carcinoma ⁷¹

Tshl ⁵⁷

Ccts ⁵⁷

St3 ⁵⁷

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Endocrine diseases

See all MalaCards categories (disease lists)

External Ids:

OMIM® ⁵⁷ 191181

EFO ¹⁶ EFO_0001061

UMLS ⁷¹ C0302592 C1860658

Sources

Summaries for Suppressor of Tumorigenicity 3

MalaCards based summary: Suppressor of Tumorigenicity 3, also known as cervical carcinoma, is related to cervical intraepithelial neoplasia and cervical squamous cell carcinoma. An important gene associated with Suppressor of Tumorigenicity 3 is ST3 (Suppression Of Tumorigenicity 3), and among its related pathways/superpathways are GPCR Pathway and Cellular responses to stimuli. The drugs Aluminum hydroxide and Monophosphoryl lipid A have been mentioned in the context of this disorder. Affiliated tissues include cervix, lymph node and t cells, and related phenotypes are neoplasm and endocrine/exocrine gland

More information from OMIM: 191181

Sources

Related Diseases for Suppressor of Tumorigenicity 3

Diseases in the Suppressor of Tumorigenicity 3 family:

Suppressor of Tumorigenicity 11

Diseases related to Suppressor of Tumorigenicity 3 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 564)

#	Related Disease	Score	Top Affiliating Genes
1	cervical intraepithelial neoplasia	31.6	FHIT CDKN2A
2	cervical squamous cell carcinoma	30.9	TP53 FHIT CDKN2A CDKN1A
3	chronic cervicitis	30.8	TP53 CDKN2A
4	cervical adenocarcinoma	30.8	TP53 CDKN2A CDKN1A
5	cervix uteri carcinoma in situ	30.7	TP53 RB1 FHIT CDKN2A
6	cervix carcinoma	30.6	TP53 MYC CDKN2A BCL2
7	adenocarcinoma	30.3	TP53 RB1 CDKN2A CDKN1A BCL2
8	basaloid squamous cell carcinoma	30.3	TP53 CDKN2A
9	keratinizing squamous cell carcinoma	30.2	TP53 CDKN2A
10	polyploidy	30.2	TP53 CDKN1A
11	endocervical adenocarcinoma	30.1	TP53 MYC CDKN2A
12	human papillomavirus infectious disease	30.0	TP53 MYC FHIT CDKN2A CDKN1A
13	papilloma	30.0	UBE3A TP53 RB1 CDKN2A CDKN1A BCL2
14	squamous cell carcinoma	29.9	TP53 RB1 MYC FHIT CDKN2A CDKN1A
15	penile benign neoplasm	29.9	TP53 CDKN2A
16	anogenital venereal wart	29.9	UBE3A TP53 RB1 CDKN2A
17	anal squamous cell carcinoma	29.9	TP53 CDKN2A
18	penile cancer	29.8	UBE3A TP53 CDKN2A
19	retinitis pigmentosa 11	29.8	TP53 MYC CDKN2A
20	lip and oral cavity cancer	29.8	TP53 RB1 CDKN2A
21	vulva squamous cell carcinoma	29.7	TP53 CDKN2A
22	retinoblastoma	29.7	TP53 RB1 MYC CDKN2A CDKN1A BCL2
23	endocervical carcinoma	29.7	TP53 MYC CDKN2A
24	acquired immunodeficiency syndrome	29.6	TP53 MYC BCL2
25	vaginal cancer	29.6	UBE3A TP53 CDKN2A
26	small cell cancer of the lung	29.5	TP53 RB1 MYC CDKN2A BCL2
27	adult t-cell leukemia/lymphoma	29.5	TP53 MYC BCL2
28	endometrial hyperplasia	29.5	TP53 CDKN2A BCL2
29	colon adenocarcinoma	29.5	TP53 MYC CDKN1A BCL2
30	teratoma	29.5	TP53 CDKN2A BCL2
31	skin carcinoma	29.4	TP53 MYC CDKN2A BCL2
32	head and neck cancer	29.4	TP53 MYC CDKN2A BCL2
33	anus cancer	29.4	UBE3A TP53 RB1 CDKN2A
34	b-cell lymphoma	29.4	TP53 RB1 MYC CDKN2A CDKN1A BCL2
35	keratoacanthoma	29.4	TP53 MYC CDKN1A BCL2
36	skin melanoma	29.4	TP53 MYC CDKN2A CDKN1A
37	osteogenic sarcoma	29.4	TP53 RB1 MYC CDKN2A CDKN1A
38	kidney cancer	29.4	TP53 FHIT CDKN2A CA9
39	peripheral nervous system disease	29.3	TP53 MYC CDKN2A BCL2
40	leiomyosarcoma	29.3	TP53 RB1 CDKN2A BCL2
41	adenoma	29.2	TP53 MYC CDKN2A BCL2
42	testicular cancer	29.2	TP53 MYC BCL2
43	pancreatic adenocarcinoma	29.1	TP53 CDKN2A CDKN1A BCL2
44	melanoma, cutaneous malignant 1	29.1	TP53 RB1 MYC CDKN2A CDKN1A
45	oropharynx cancer	29.1	UBE3A TP53 CDKN2A BCL2
46	basal cell carcinoma	29.1	TP53 CDKN2A CDKN1A BCL2
47	fanconi anemia, complementation group a	29.1	TP53 RB1 MYC CDKN2A CDKN1A
48	nasopharyngeal carcinoma	29.0	TP53 MYC CDKN2A CA9 BCL2
49	myelodysplastic syndrome	29.0	TP53 MYC FHIT CDKN2A BCL2
50	glioblastoma	29.0	TP53 RB1 MYC CDKN2A CDKN1A BCL2

Graphical network of the top 20 diseases related to Suppressor of Tumorigenicity 3:

Sources

Symptoms & Phenotypes for Suppressor of Tumorigenicity 3

Clinical features from OMIM®:

191181 (Updated 08-Dec-2022)

MGI Mouse Phenotypes related to Suppressor of Tumorigenicity 3:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	neoplasm	MP:0002006	10.06	BCL2 CDKN1A CDKN2A FHIT MYC RB1
2	endocrine/exocrine gland	MP:0005379	9.92	BCL2 CA9 CDKN1A CDKN2A MYC RB1
3	no phenotypic analysis	MP:0003012	9.91	CDKN1A CDKN2A MYC RB1 TP53 UBE3A
4	pigmentation	MP:0001186	9.88	BCL2 CDKN2A MYC RB1 TP53
5	adipose tissue	MP:0005375	9.88	BCL2 CDKN1A MYC PLIN3 RB1 TP53
6	digestive/alimentary	MP:0005381	9.86	BCL2 CA9 CDKN1A CDKN2A FHIT MYC
7	immune system	MP:0005387	9.81	BCL2 CA9 CDKN1A CDKN2A FHIT MYC
8	hearing/vestibular/ear	MP:0005377	9.77	BCL2 CDKN1A MYC RB1 TP53
9	hematopoietic system	MP:0005397	9.65	BCL2 CA9 CDKN1A CDKN2A FHIT MYC
10	integument	MP:0010771	9.28	BCL2 CDKN1A CDKN2A FHIT MYC RB1

Sources

Drugs & Therapeutics for Suppressor of Tumorigenicity 3

Drugs for Suppressor of Tumorigenicity 3 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 146)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Aluminum hydroxide

Approved, Investigational

Phase 4

21645-51-2

Monophosphoryl lipid A

Phase 4

Vaccines

Phase 4

Immunologic Factors

Phase 4

Bevacizumab

Approved, Investigational

Phase 3

216974-75-3

135329020

Metronidazole

Approved

Phase 2, Phase 3

443-48-1, 69198-10-3

4173

Doxorubicin

Approved, Investigational

Phase 3

23214-92-8

31703

Topotecan

Approved, Investigational

Phase 3

123948-87-8, 119413-54-6

60699 60700

Vinorelbine

Approved, Investigational

Phase 3

71486-22-1

44424639 60780

Cemiplimab

Approved, Investigational

Phase 3

1801342-60-8

Pemetrexed

Approved, Investigational

Phase 3

150399-23-8, 137281-23-3

60843 446556 135565230

Gemcitabine

Approved

Phase 3

95058-81-4, 122111-03-9

60750

Inulin

Approved, Investigational, Nutraceutical

Phase 3

9005-80-5

24763

D-Tyrosine

Approved, Experimental, Investigational, Nutraceutical

Phase 3

133585-56-5, 60-18-4, 556-02-5

1153 6057

Tirapazamine

Investigational

Phase 3

27314-97-2

135413511

Endostatins

Phase 3

Endostar protein

Phase 3

topoisomerase I inhibitors

Phase 3

Endothelial Growth Factors

Phase 3

Mitogens

Phase 3

Anti-Infective Agents

Phase 2, Phase 3

Antiprotozoal Agents

Phase 2, Phase 3

Antiparasitic Agents

Phase 2, Phase 3

Anti-Bacterial Agents

Phase 3

Antibiotics, Antitubercular

Phase 3

Liposomal doxorubicin

Phase 3

Folic Acid Antagonists

Phase 3

Vinca Alkaloids

Phase 3

Etoposide

Approved

Phase 2

33419-42-0

36462

Darbepoetin alfa

Approved, Investigational

Phase 2

209810-58-2

Mycophenolic acid

Approved, Investigational

Phase 2

24280-93-1

446541

Miconazole

Approved, Investigational, Vet_approved

Phase 2

22916-47-8

4189

Clotrimazole

Approved, Vet_approved

Phase 2

23593-75-1

2812

Arsenic trioxide

Approved, Investigational

Phase 2

1327-53-3

518740

Docetaxel

Approved, Investigational

Phase 2

114977-28-5

148124

Cetuximab

Approved

Phase 2

205923-56-4

Sirolimus

Approved, Investigational

Phase 2

53123-88-9

5284616 6436030

Bupropion

Approved

Phase 2

31677-93-7, 34841-39-9, 34911-55-2

444

Dopamine

Approved

Phase 2

62-31-7, 51-61-6

681

Celecoxib

Approved, Investigational

Phase 2

169590-42-5

2662

Capecitabine

Approved, Investigational

Phase 2

154361-50-9

60953

Oxaliplatin

Approved, Investigational

Phase 2

61825-94-3

43805 11947679 6857599

Lenograstim

Approved, Investigational

Phase 2

135968-09-1

Atezolizumab

Approved, Investigational

Phase 2

1380723-44-3

Pembrolizumab

Approved

Phase 2

1374853-91-4

254741536

Racepinephrine

Approved, Vet_approved

Phase 2

51-43-4, 329-65-7

838 5816

Afatinib

Approved

Phase 2

439081-18-2, 850140-72-6

53445376 10184653

Adenosine

Approved, Investigational

Phase 2

58-61-7

60961

Trametinib

Approved

Phase 2

871700-17-3

11707110

Palbociclib

Approved, Investigational

Phase 2

571190-30-2

5330286

Interventional clinical trials:

(show top 50) (show all 183)

#	Name	Status	NCT ID	Phase	Drugs
1	HPV Vaccination Impact on Cervical Cancer Screening Program: FASTER-Tlalpan Study in Mexico	Completed	NCT03105856	Phase 4
2	Single-Dose HPV Vaccination Among Young Adult Women in Costa Rica: the PRISMA-ESCUDDO Trial (PRevencIón Del Cáncer Cervical Con Una Sola Dosis de Vacuna Contra VPH en Mujeres Adultas Jóvenes)	Enrolling by invitation	NCT05237947	Phase 4
3	A Scientific Evaluation of One or Two Doses of Vaccine Against Human Papillomavirus: the ESCUDDO Study ("Estudio de Comparacion de Una y Dos Dosis de Vacunas Contra el Virus de Papiloma Humano (VPH)")	Enrolling by invitation	NCT03180034	Phase 4
4	Comparison of Different Adjuvant Treatments Following Radical Surgery in Early Stage Cervical Carcinoma	Unknown status	NCT00806117	Phase 3
5	A Multicenter, Randomized Controlled Clinical Trial Comparing Endostar With Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy in the Treatment of Locally Advanced Cervical Carcinoma	Unknown status	NCT03086681	Phase 3	Endostar;DDP
6	Comparing Standard Concurrent Chemo-radiation to Neoadjuvant Chemotherapy Then Surgery or Radiation in Patients Stage Ib2-early IIb Cervical Carcinoma	Unknown status	NCT01000415	Phase 3
7	Phase II/III Clinical Trial of Intensity Modulated Radiation Therapy With Concurrent Cisplatin for Stage I-IVA Cervical Carcinoma	Unknown status	NCT01554397	Phase 2, Phase 3	Cisplatin
8	A Double-blind Placebo-controlled Trial of Dietary Supplementation With 15g/Day FOS for Five Weeks in Patients With Endometrial/Cervical Carcinoma or 7.5 Weeks in Patients With Prostate Carcinoma Undergoing Pelvic Radiotherapy.	Unknown status	NCT01414517	Phase 3
9	Neoadjuvant Chemotherapy and Radical Surgery Versus Concurrent Chemoirradiation in FIGO Stage IIB Cervical Cancer	Unknown status	NCT02595554	Phase 3	Paclitaxel;Cisplatin
10	Phase III Clinical Trial: "Evaluation of the Combination of Nimotuzumab and Cisplatin-Vinorelbine in First Line Chemotherapy in the Survival of Patients With Recurring-Persistent Cervical Carcinoma"	Completed	NCT02083211	Phase 3	mAb Nimotuzumab
11	Multicenter Randomised Double-blind Study to Compare HR3 or Placebo in Combination With Cisplatin-navelbine for Patients With Cervical Carcinoma, Followed in Case of Progression by a Second Line.	Completed	NCT03413579	Phase 3
12	To Study the Factors Affecting Treatment Responses in Patients With Uterine Cervical Carcinoma Undergoing Neoadjuvant Chemotherapy	Completed	NCT05384366	Phase 3	Neoadjuvant chemotherapy
13	A Randomized Phase III Trial of Cisplatin Plus Paclitaxel With and Without NCI-Supplied Bevacizumab (NSC #704865) Versus the Non-platinum Doublet, Topotecan Plus Paclitaxel, With and Without NCI-Supplied Bevacizumab, in Stage IVB, Recurrent or Persistent Carcinoma of the Cervix	Completed	NCT00803062	Phase 3	Cisplatin;Paclitaxel;Topotecan Hydrochloride
14	A Randomized Phase III Trial Of Paclitaxel Plus Cisplatin Versus Vinorelbine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Versus Topotecan Plus Cisplatin In Stage IVB, Recurrent Or Persistent Carcinoma of the Cervix	Completed	NCT00064077	Phase 3	Cisplatin;Gemcitabine Hydrochloride;Paclitaxel;Topotecan Hydrochloride;Vinorelbine Tartrate
15	A Randomized Clinical Trial of Radiotherapy and Metronidazole Versus Radiotherapy Alone in Anaemic Patients With Advanced Cervical Cancer In Mulago	Completed	NCT01937650	Phase 2, Phase 3	Radiotherapy plus metronidazole
16	Collaborative Corneal Transplantation Studies (CCTS)	Completed	NCT00000137	Phase 3
17	A Phase 1/2a/3 Evaluation of the Safety and Efficacy of Adding AL3818 (Anlotinib, INN: Catequentinib), a Dual Receptor Tyrosine Kinase Inhibitor, to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma	Recruiting	NCT02584478	Phase 3	AL3818;Paclitaxel;Pegylated Liposomal Doxorubicin (PLD);Topotecan;Carboplatin
18	A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate AK104 Combined With Chemoradiotherapy For The Treatment of Locally Advanced Cervical Cancer	Recruiting	NCT05235516	Phase 3	AK104;cisplatin;Placebo
19	An Open-Label, Randomized, Phase 3 Clinical Trial of REGN2810 Versus Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Carcinoma	Active, not recruiting	NCT03257267	Phase 3	Cemiplimab;Investigator Choice (IC) Chemotherapy
20	Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy With or Without Adjuvant Chemotherapy in High-Risk Patients With Early-Stage Cervical Carcinoma Following Radical Hysterectomy	Active, not recruiting	NCT00980954	Phase 3	carboplatin;cisplatin;paclitaxel
21	Non-Inferiority Trial Comparing Immunogenicity From 1-Dose of Bivalent HPV Vaccine in Girls to 3-Doses of Quadrivalent Vaccine in Women: The PRIMAVERA-ESCUDDO Trial ("Puente de Respuesta Inmunológica Para Mejorar el Acceso a Vacunas y ERrAdicar el Cancer")	Active, not recruiting	NCT03728881	Phase 3
22	PARa-aOrtic LymphAdenectomy in Locally Advanced Cervical Cancer.	Not yet recruiting	NCT05581121	Phase 3
23	A Phase III, Randomized Trial of Weekly Cisplatin and Radiation Versus Cisplatin and Tirapazamine and Radiation in Stage IB2, IIA, IIIB and IVA Cervical Carcinoma Limited to the Pelvis	Terminated	NCT00262821	Phase 3	cisplatin;tirapazamine
24	Anti-PD-1 Antibody Camrelizumab Combined With Cisplatin/Paclitaxel/Bevacizumab for Recurrent or Advanced Cervical Neuroendocrine Carcinomas: A Single Arm, Phase II Trial	Unknown status	NCT04635956	Phase 2	Drug therapy
25	Phase II Study of NESP (Novel Erythropoiesis Stimulating Protein) During Concurrent Chemo-Radiation for the Treatment of Cervical Carcinoma.	Unknown status	NCT00039884	Phase 2	NESP - Novel Erythropoiesis Stimulating Protein
26	An Exploratory Pharmacogenomic Study of Neoadjuvant Cetuximab Followed by Cisplatin, Radiotherapy, and Cetuximab in Women With Newly Diagnosed Locally Advanced or Metastatic Cervical Carcinoma	Unknown status	NCT00292955	Phase 2	Cetuximab
27	An Open Label Randomized Phase 2, Pilot Study to Investigate the Effectiveness of Palliative Chemotherapy in Stage IVB, Recurrent or Persistent Carcinoma Cervix	Unknown status	NCT02492503	Phase 1, Phase 2	Paclitaxel and carboplatin
28	Efficacy of the Oncoxin-Viusid® Oral Solution in Reducing the Adverse Reactions of Chemotherapy and Radiotherapy in Patients Diagnosed With Cervical Cancer and Endometrial Adenocarcinoma.	Completed	NCT03540407	Phase 2
29	Apatinib Combined With Cisplatin and Paclitaxel as First-line Chemotherapy for Recurrent or Persistent Advanced Cervical Cancer: A Single Arm, Single Center, Open, Phase II Trial	Completed	NCT04188847	Phase 2	Chemotherapy plus apatinib
30	Anti-PD-1 Antibody Camrelizumab Combined With Albumin-bound Paclitaxel for Recurrent and Persistent Advanced Cervical Cancer Refractory to Platinum-based Chemotherapy: A Single Arm, Single Center, Open, Phase II Trial	Completed	NCT04188860	Phase 2	A combination of anti-PD-1 antibody camrelizumab and albumin-bound paclitaxel
31	A PHASE II STUDY OF BEVACIZUMAB IN COMBINATION WITH DEFINITIVE RADIOTHERAPY AND CISPLATIN CHEMOTHERAPY IN UNTREATED PATIENTS WITH LOCALLY ADVANCED CERVICAL CARCINOMA	Completed	NCT00369122	Phase 2	Cisplatin
32	A Phase 2 Study of Ipilimumab in Women With Metastatic or Recurrent HPV-Related Cervical Carcinoma of Either Squamous Cell or Adenocarcinoma Histologies	Completed	NCT01693783	Phase 2
33	A Phase II Study of Sunitinib (SU11248; NSC 736511) an Oral Multi-Targeted Tyrosine Kinase Inhibitor, in Patients With Unresectable, Locally Advanced or Metastatic Cervical Carcinoma	Completed	NCT00389974	Phase 2	sunitinib malate
34	Phase II Pilot Trial of Non-Myeloablative Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation Using Fludarabine, Low Dose TBI and Post-Transplant Cyclosporine and Mycophenolate Mofetil Followed by Donor Lymphocyte Infusion for Therapy of Advanced or Metastatic Human Papilloma Virus (HPV) - Associated Cervical Carcinoma Refractory to Standard Therapy	Completed	NCT00005941	Phase 2	cyclosporine;fludarabine phosphate;mycophenolate mofetil
35	A Phase II Study of Arsenic Trioxide (NSC #706363) in Patients With Advanced Cervical Carcinoma	Completed	NCT00005999	Phase 2	arsenic trioxide
36	Neoadjuvant Chemotherapy With Docetaxel in Advanced Cervical Carcinoma	Completed	NCT00003445	Phase 2	docetaxel
37	HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA） for Cervical Carcinoma: Clinical Trial	Completed	NCT02523365	Phase 1, Phase 2
38	Phase I/II Study of Gemcitabine and Concurrent Radiation Followed by Adjuvant Hysterectomy in Bulky Stage Ib and IIa Cervical Carcinoma: Analysis of Prognostic Factors and Determinants of Response: A Pilot Study	Completed	NCT00184093	Phase 1, Phase 2	Gemcitabine
39	A Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Advanced Cervical Carcinoma	Completed	NCT00005070	Phase 2	irofulven
40	A Phase I/II Study Of Whole Pelvic Radiation Therapy With Concomitant Paclitaxel and Cisplatin Chemotherapy in Patients With Cervical Carcinoma (Stages I-IV) Limited to the Pelvis	Completed	NCT00003379	Phase 1, Phase 2	cisplatin;paclitaxel
41	A Phase II Study of Intensity Modulated Radiation Therapy (IMRT) to the Pelvis ± Chemotherapy for Post-Operative Patients With Either Endometrial or Cervical Carcinoma	Completed	NCT00331760	Phase 2	cisplatin
42	A Pilot Study of Weekly IV Topotecan and Cisplatin With Concurrent Pelvic Radiation in the Treatment of Stages IB2 - IVA Cervical Carcinoma	Completed	NCT00257816	Phase 2	Topotecan;Cisplatin
43	A Phase II, Open-label Study of Efficacy and Safety of the Selective Inhibitor of Nuclear Export/SINE™ Compound KPT-330 (Selinexor) in Patients With Advanced Gynaecologic Malignancies	Completed	NCT02025985	Phase 2	Selinexor
44	A Phase II Evaluation of Cetuximab (Erbitux®, C225, NSC# 714692) in the Treatment of Persistent or Recurrent Squamous or Non-Squamous Cell Carcinoma of the Cervix	Completed	NCT00499031	Phase 2
45	A Phase II Evaluation Of Docetaxel (NSC #628503) In The Treatment Of Persistent Or Recurrent Squamous Cell Carcinoma Of The Cervix	Completed	NCT00041093	Phase 2	Docetaxel
46	Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women With Breast or Gynecologic Cancer	Completed	NCT03180294	Phase 2	Bupropion 150 mg XL;Placebo
47	A Randomized Double-Blind Phase II Trial of Celecoxib, A COX-2 Inhibitor, in the Treatment of Patients With Cervical Intraepithelial Neoplasia 2/3 or 3 (CIN 2/3 or 3)	Completed	NCT00081263	Phase 2	Celecoxib
48	A Phase II Evaluation Of Capecitabine (NSC #712807) In The Treatment Of Persistent Or Recurrent Non-Squamous Cell Carcinoma Of The Cervix	Completed	NCT00039442	Phase 2	Capecitabine
49	A Phase II Study of Oxaliplatin in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Cervical Cancer	Completed	NCT00057863	Phase 2	Paclitaxel;Oxaliplatin
50	Prospective Evaluation of Pelvic Exenteration in Patients With Recurrent Cervical Cancer	Completed	NCT00217633	Phase 2

Search NIH Clinical Center for Suppressor of Tumorigenicity 3

Sources

Genetic Tests for Suppressor of Tumorigenicity 3

Sources

Anatomical Context for Suppressor of Tumorigenicity 3

Organs/tissues related to Suppressor of Tumorigenicity 3:

MalaCards : Cervix, Lymph Node, T Cells, Breast, Bone Marrow, Prostate, Lung

Sources

Publications for Suppressor of Tumorigenicity 3

Articles related to Suppressor of Tumorigenicity 3:

(show top 50) (show all 12419)

#	Title	Authors	PMID	Year
1	Interstitial deletion of 11q13 sequences in HeLa cells. ⁶² ⁵⁷	Srivatsan ES...Redpath JL	10959095	2000
2	Deletion and translocation of chromosome 11q13 sequences in cervical carcinoma cell lines. ⁶² ⁵⁷	Jesudasan RA...Srivatsan ES	7887426	1995
3	Loss of heterozygosity in cervical carcinoma: subchromosomal localization of a putative tumor-suppressor gene to chromosome 11q22-q24. ⁶² ⁵⁷	Hampton GM...Bird CC	8041728	1994
4	Loss of heterozygosity for alleles on chromosome II in cervical carcinoma. ⁶² ⁵⁷	Srivatsan ES...Wilczynski SP	1680288	1991
5	Genetic characteristics of the HeLa cell. ⁶² ⁵⁷	Hsu SH...Bodmer WF	1246620	1976
6	Short tandem repeat profiling provides an international reference standard for human cell lines. ⁵⁷	Masters JR...Debenham PG	11416159	2001
7	Cell culture forensics. ⁵⁷	O'Brien SJ	11438719	2001
8	East Hela and West Hela, in memory of Stella Mamaeva, 1939-1995. ⁵⁷	Chen TR	8964054	1996
9	Localization of HeLa cell tumor-suppressor gene to the long arm of chromosome II. ⁵⁷	Misra BC...Srivatsan ES	2577469	1989
10	Introduction of human chromosome 11 via microcell transfer controls tumorigenic expression of HeLa cells. ⁵⁷	Saxon PJ...Stanbridge EJ	2881780	1986
11	Implication of chromosome 11 in the suppression of neoplastic expression in human cell hybrids. ⁵⁷	Srivatsan ES...Stanbridge EJ	2877730	1986
12	Suppression of tumorigenicity in somatic cell hybrids. III. Cosegregation of human chromosome 11 of a normal cell and suppression of tumorigenicity in intraspecies hybrids of normal diploid x malignant cells. ⁵⁷	Kaelbling M...Klinger HP	3956263	1986
13	Suppression of tumorigenicity. ⁵⁷	Klinger HP	7140370	1982
14	Specific chromosome loss associated with the expression of tumorigenicity in human cell hybrids. ⁵⁷	Stanbridge EJ...Nelson-Rees WA	7323948	1981
15	Cross-contamination of cells in culture. ⁵⁷	Nelson-Rees WA...Flandermeyer RR	6451928	1981
16	Suppression of tumorigenicity in somatic cell hybrids. I. Suppression and reexpression of tumorigenicity in diploid human X D98AH2 hybrids and independent segregation of tumorigenicity from other cell phenotypes. ⁵⁷	Klinger HP	6934067	1980
17	Characteristics of HeLa strains: permanent vs. variable features. ⁵⁷	Nelson-Rees WA...O'Brien SJ	7002488	1980
18	Suppression of malignancy in human cells. ⁵⁷	Stanbridge EJ	1264187	1976
19	HeLa cultures defined. ⁵⁷	Nelson-Rees WA...Flandermeyer RR	1246601	1976
20	Banded marker chromosomes as indicators of intraspecies cellular contamination. ⁵⁷	Nelson-Rees WA...Hawthorne PK	4469665	1974
21	George Otto Gey. (1899-1970). The HeLa cell and a reappraisal of its origin. ⁵⁷	Jones HW...Wuu KD	4942173	1971
22	Apparent Hela cell contamination of human heteroploid cell lines. ⁵⁷	Gartler SM	5641128	1968
23	MicroRNA-34a suppresses invasion through downregulation of Notch1 and Jagged1 in cervical carcinoma and choriocarcinoma cells. ⁵³ ⁶²	Pang RT...Yeung WS	20351093	2010
24	Increased cytotoxicity of an unusual DNA topoisomerase II inhibitor compound C-1305 toward HeLa cells with downregulated PARP-1 activity results from re-activation of the p53 pathway and modulation of mitotic checkpoints. ⁵³ ⁶²	Sabisz M...Skladanowski A	20067769	2010
25	Vascular endothelial growth factor C promotes cervical cancer metastasis via up-regulation and activation of RhoA/ROCK-2/moesin cascade. ⁵³ ⁶²	He M...Fu X	20429915	2010
26	Constitutive HIF-1 activity in malignant melanoma. ⁵³ ⁶²	Kuphal S...Bosserhoff AK	20185296	2010
27	Rescue of p53 function by small-molecule RITA in cervical carcinoma by blocking E6-mediated degradation. ⁵³ ⁶²	Zhao CY...Selivanova G	20395210	2010
28	HER2 codon 655 polymorphism is associated with advanced uterine cervical carcinoma. ⁵³ ⁶²	Kruszyna L...Jagodzinski PP	20026098	2010
29	Notch1 regulates the functional contribution of RhoC to cervical carcinoma progression. ⁵³ ⁶²	Srivastava S...Krishna S	19953094	2010
30	Overexpression of phosphorylated 4E-BP1 predicts for tumor recurrence and reduced survival in cervical carcinoma treated with postoperative radiotherapy. ⁵³ ⁶²	Benavente S...Giralt J	19362787	2009
31	Wogonin induces G1 phase arrest through inhibiting Cdk4 and cyclin D1 concomitant with an elevation in p21Cip1 in human cervical carcinoma HeLa cells. ⁵³ ⁶²	Yang L...Guo QL	19935879	2009
32	[Involvement of human papillomavirus in upper aero-digestive tracts cancers]. ⁵³ ⁶²	Neufcoeur PE...Saussez S	19744917	2009
33	HER2/neu (c-erbB-2) gene amplification and protein expression are rare in uterine cervical neoplasia: a tissue microarray study of 814 archival specimens. ⁵³ ⁶²	Lesnikova I...Koch J	19775342	2009
34	Identification of an active site of EMMPRIN for the augmentation of matrix metalloproteinase-1 and -3 expression in a co-culture of human uterine cervical carcinoma cells and fibroblasts. ⁵³ ⁶²	Sato T...Ito A	19427027	2009
35	The role of VEGF-C/D and Flt-4 in the lymphatic metastasis of early-stage invasive cervical carcinoma. ⁵³ ⁶²	Yu H...Zhang L	19589137	2009
36	Spatiotemporal activation of caspase-dependent and -independent pathways in staurosporine-induced apoptosis of p53wt and p53mt human cervical carcinoma cells. ⁵³ ⁶²	Nicolier M...Mougin C	19216720	2009
37	The association of XRCC1 gene single nucleotide polymorphisms with response to neoadjuvant chemotherapy in locally advanced cervical carcinoma. ⁵³ ⁶²	Cheng XD...Xie X	19563645	2009
38	Antitumor activity of small double-stranded oligodeoxynucleotides targeting telomerase RNA in malignant melanoma cells. ⁵³ ⁶²	Noreen F...Moelling K	19441892	2009
39	Single nucleotide polymorphisms in antigen processing machinery component ERAP1 significantly associate with clinical outcome in cervical carcinoma. ⁵³ ⁶²	Mehta AM...Jan Fleuren G	19202550	2009
40	Expressions of IGFBP-5, cFLIP in cervical intraepithelial neoplasia, cervical carcinoma and their clinical significances: a molecular pathology. ⁵³ ⁶²	Hou XJ...Qiao YB	19476635	2009
41	[Inhibitive effect of E1A gene on the cell growth of human cervical carcinoma cell in vitro]. ⁵³ ⁶²	Ouyang H...Shen L	19483289	2009
42	The association between the survivin C-31G polymorphism and gastric cancer risk in a Chinese population. ⁵³ ⁶²	Yang L...Wang B	18716870	2009
43	Immunohistochemical studies of trophoblastic tumors. ⁵³ ⁶²	Kalhor N...Silva EG	19145204	2009
44	Identification of novel fibroblast growth factor receptor 3 gene mutations in actinic cheilitis and squamous cell carcinoma of the lip. ⁵³ ⁶²	Chou A...Jordan RC	19327639	2009
45	No association of TAP1 and TAP2 genes polymorphism with risk of cervical cancer in north Indian population. ⁵³ ⁶²	Kordi Tamandani DM...Suri V	19263211	2009
46	Differential tissue-specific protein markers of vaginal carcinoma. ⁵³ ⁶²	Hellman K...Auer G	19367286	2009
47	Major vault protein may affect nonhomologous end-joining repair and apoptosis through Ku70/80 and bax downregulation in cervical carcinoma tumors. ⁵³ ⁶²	Lloret M...Falcon O	19251084	2009
48	Transition of cervical carcinoma in situ to invasive cancer: role of p16 INK4a expression in progression and in recurrence. ⁵³ ⁶²	Anschau F...Machado DC	19100258	2009
49	Preliminary study of TIP47 as a possible new biomarker of cervical dysplasia and invasive carcinoma. ⁵³ ⁶²	Szigeti A...Bellyei S	19331227	2009
50	Mutation of PIK3CA: possible risk factor for cervical carcinogenesis in older women. ⁵³ ⁶²	Cui B...Wallin KL	19148475	2009

Sources

Genes for Suppressor of Tumorigenicity 3

Genes related to Suppressor of Tumorigenicity 3 (1 elite genes):

(show all 13)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	ST3	Suppression Of Tumorigenicity 3	Genetic Locus	50	Genetic linkage ⁵⁷
2	TP53	Tumor Protein P53	Protein Coding	9.24	Novoseek inferred ⁵³	10374328 10813720 10072870 (more) 8630877 9334921 10098748 15617346 11378660 11769670 19145674 11574134 8388491 17685229 8920796 1363512 8393371 11023067 8142262 8238255 12451999 9470836 14670624 11148563 9662253 10739702 8018409 8384745 1646990 17671528 9772303 16289387 10719811 8302581 10607922 9208900 12908520 17310826 1322242 8806692 10900010 9788606 9367711 13678722 7503188 7718254 8433212 8380785 1648361 9219832 8706159 8745488 8152158 1352566 12190289 11396132 8674562 9648588 19657726 18439073 10329038 19216720 17352217 16026074 1327506 17567683 15047823 10567656 20395210 1648218 8387205 12504622 17192686 15378004 15202785 14681700 12795334 12713987 12431761 12144687 15380586 7910219 8229452 8397367 8389030 1327751 19660100 19744917 15262117 10817508 10729761 10491526 9790785 9162297 8631546 8601524 17290384 17208232 15201979 15116093
3	FHIT	Fragile Histidine Triad Diadenosine Triphosphatase	Protein Coding	8.52	Novoseek inferred ⁵³	15573771 9354423 19471558 (more) 16078573 10999736 12893195 14660280 10675384 10585575 17671528 11004671 11891319 9187105 12657123 11389064 10027335 18494825 12355215 9537577 10223242 18608185 9928473 9537583 16865265 9242443 11350899
4	RB1	RB Transcriptional Corepressor 1	Protein Coding	7.89	Novoseek inferred ⁵³	15617346 10329038 1648361 (more) 10393912 1668886 1316611 1322242 15767426 9772434 10491526 15575375 11004671 11503038 11161855 14506250 1309779 10082538
5	PLIN3	Perilipin 3	Protein Coding	7.72	Novoseek inferred ⁵³	19331227 11299819 9874244 (more) 10697545
6	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	7.5	Novoseek inferred ⁵³	12948409 17359536 15730957 (more) 9648588 12911724 9698478 16027780 17697601 17521451 20112504 16259056 16633070 20432728 19851197 18365017 11448914 18722107 19256750 19142477 18301453 15575375 8821952 19514374 17672936 19100258 16494930 19145204 9159345 10535995 9166931 16677523 16415792
7	MYC	MYC Proto-Oncogene, BHLH Transcription Factor	Protein Coding	7.04	Novoseek inferred ⁵³	12948409 8414499 1619315 (more) 9648593 14729369 15491757 9673366 15585135 10583438 9891436 8289968 10082554 8519685 11134351 7641187 11803460 1721614 9291819 1326470
8	ENOX2	Ecto-NOX Disulfide-Thiol Exchanger 2	Protein Coding	6.92	Novoseek inferred ⁵³	16129553 16444599 15706060 (more) 18351130
9	CDKN1A	Cyclin Dependent Kinase Inhibitor 1A	Protein Coding	6.66	Novoseek inferred ⁵³	19657726 9568185 11179504 (more) 10329038 16026074 18425078 19935879 12795334 11956602 17685229 9524287 11595134 1707025 12392301 16677523
10	UBE3A	Ubiquitin Protein Ligase E3A	Protein Coding	6.66	Novoseek inferred ⁵³	8397367 15731267
11	BCL2	BCL2 Apoptosis Regulator	Protein Coding	6.56	Novoseek inferred ⁵³	11769670 18788571 9465813 (more) 7768985 9059353 11809111 17464868 10618615 15889622 10739702 9703806 9808425 8691340 12504622 10037278 9655299 19362787 14558950 15899779 11956602 17713095 9162297 9421084 11775218 12440815 15201979 15380586 15917408
12	CA9	Carbonic Anhydrase 9	Protein Coding	6.48	Novoseek inferred ⁵³	12687273 14654550 18055005
13	TAP1	Transporter 1, ATP Binding Cassette Subfamily B Member	Protein Coding	6.47	Novoseek inferred ⁵³	8270878 11713591 17382375 (more) 19263211 8198988 17622526 17366619 7640226 19202550

Sources

Variations for Suppressor of Tumorigenicity 3

Sources

Expression for Suppressor of Tumorigenicity 3

Search GEO for disease gene expression data for Suppressor of Tumorigenicity 3.

Sources

Pathways for Suppressor of Tumorigenicity 3

Pathways related to Suppressor of Tumorigenicity 3 according to GeneCards Suite gene sharing:

(show top 50) (show all 58)

#	Super pathways	Score	Top Affiliating Genes
1	GPCR Pathway ⁶⁴ Show member pathways Breast Cancer Regulation by Stathmin1 ⁶⁴ Estrogen Pathway ⁶⁴ NFAT in Immune Response ⁶⁴ P2Y Receptor Signaling ⁶⁴ Pancreatic Adenocarcinoma ⁶⁴ Paxillin Interactions ⁶⁴ Ras Pathway ⁶⁴	13.61	UBE3A TP53 RB1 MYC CDKN2A CDKN1A
2	Cellular responses to stimuli ⁶⁶ Show member pathways Cellular responses to stress ⁶⁶	13.39	TP53 RB1 MYC CDKN2A CDKN1A CA9
3	Prolactin Signaling ⁶⁴ Show member pathways Development Prolactin receptor signaling ²² EGFR Inhibitor Pathway, Pharmacodynamics ⁶⁰ EGFR tyrosine kinase inhibitor resistance ⁷⁴ ErbB Family Pathway ⁶⁴ ErbB signaling pathway ⁷⁴ ErbB2-ErbB3 Heterodimers ⁶⁴ ErbB4 Pathway ⁶⁴ Estrogen-stimulated signaling through PRKCZ ⁶⁶ Glioblastoma Multiforme ⁶⁴ Glioblastoma signaling pathways ⁷⁴ Growth Hormone Signaling ⁶⁴ HMGB1 Pathway ⁶⁴ IL-2 Pathway ⁶⁴ LPS Stimulated MAPK Signaling ⁶⁴ PACAP Signaling ⁶⁴ PI3K Signaling in B-Lymphocyte ⁶⁴ TCA cycle nutrient use and invasiveness of ovarian cancer ⁷⁴ Thrombopoietin Pathway ⁶⁴ TREM1 Pathway ⁶⁴ UVA-Induced MAPK Signaling ⁶⁴ UVB-Induced MAPK Signaling ⁶⁴ UVC-Induced MAPK Signaling ⁶⁴	13.38	TP53 RB1 MYC CDKN2A CDKN1A BCL2
4	TNFR1 Pathway ⁶⁴ Show member pathways Apoptosis ⁷⁴ Apoptosis and survival TNFR1 signaling pathway ²² Apoptosis modulation by HSP70 ⁷⁴ Apoptosis through Death Receptors ⁶⁴ Apoptotic Pathways Triggered By HIV1 ⁶⁴ Ceramide signaling pathway ⁶¹ DR3 Signaling ⁶⁴ GITR Pathway ⁶⁴ HIV-1 Nef: Negative effector of Fas and TNF-alpha ⁶¹ Stimulation of the cell death response by PAK-2p34 ⁶⁶ TNF Signaling ⁶⁴ TNF-related weak inducer of apoptosis (TWEAK) signaling pathway ⁷⁴ TRAIL Pathway ⁶⁴ TWEAK Pathway ⁶⁴	12.85	TP53 MYC CDKN2A CDKN1A BCL2
5	Cellular Senescence ⁶⁶ Show member pathways Oxidative Stress Induced Senescence ⁶⁶ Senescence-Associated Secretory Phenotype (SASP) ⁶⁶	12.65	CDKN1A CDKN2A RB1 TP53
6	Malignant pleural mesothelioma ⁷⁴	12.63	BCL2 CDKN1A CDKN2A MYC TP53
7	Immune response IL-23 signaling pathway ²² Show member pathways Angiopoietin receptor Tie2-mediated signaling ⁶¹ Angiopoietin-TIE2 Signaling ⁶⁴ Development Angiopoietin - Tie2 signaling ²² Development PDGF signaling via STATs and NF-kB ²² IL23-mediated signaling events ⁶¹ Immune response IL-10 signaling pathway ²² RAC1/PAK1/p38/MMP2 pathway ⁷⁴	12.53	TP53 MYC CDKN1A BCL2
8	Chks in Checkpoint Regulation ⁶⁴ Show member pathways DNA Repair Mechanisms ⁶⁴ Estrogen-mediated S-Phase Entry ⁶⁴ G2-M Phase Transition ⁶⁴ SREBP Proteolysis ⁶⁴	12.53	TP53 RB1 MYC CDKN1A BCL2
9	Endometrial cancer ⁷⁴ Show member pathways Chromosomal and microsatellite instability in colorectal cancer ⁷⁴ Melanoma ⁷⁴ Non-small cell lung cancer ⁷⁴ Pancreatic adenocarcinoma pathway ⁷⁴ Signal transduction PTEN pathway ²²	12.49	BCL2 CDKN1A CDKN2A FHIT MYC RB1
10	DNA Damage ³	12.46	TP53 RB1 CDKN2A CDKN1A
11	Mitotic G1 phase and G1/S transition ⁶⁶ Show member pathways G1/S Transition ⁶⁶	12.43	RB1 MYC CDKN2A CDKN1A
12	Breast cancer pathway ⁷⁴ Show member pathways Embryonic stem cell pluripotency pathways ⁷⁴	12.4	TP53 RB1 MYC CDKN1A
13	Cell cycle Regulation of G1/S transition (part 1) ²² Show member pathways Cell cycle ESR1 regulation of G1/S transition ²² Cell cycle Role of SCF complex in cell cycle regulation ²² Immune response MIF-JAB1 signaling ²² Mitotic Roles of Polo Like Kinases ⁶⁴	12.31	RB1 MYC CDKN2A CDKN1A
14	Vitamin D receptor pathway ⁷⁴	12.21	MYC CDKN2A CDKN1A CA9
15	p53 Signaling ⁶⁴ Show member pathways p53 Pathway ⁶⁷	12.16	TP53 RB1 CDKN1A BCL2
16	MAPK Signaling: Mitogens ⁶⁵ Show member pathways Akt Signaling Pathway ⁶⁵	12.14	TP53 RB1 MYC CDKN1A BCL2
17	Cell cycle ⁷⁴ Show member pathways G1 to S cell cycle control ⁷⁴	12.14	TP53 RB1 MYC CDKN2A CDKN1A
18	Colorectal Cancer Metastasis ⁶⁴	12.11	TP53 MYC CDKN1A
19	Integrated breast cancer pathway ⁷⁴	12.09	TP53 RB1 MYC BCL2
20	T-cell activation SARS-CoV-2 ⁷⁴ Show member pathways T-cell antigen receptor (TCR) pathway during Staphylococcus aureus infection ⁷⁴	12.07	TP53 CDKN2A CDKN1A
21	miRNA regulation of DNA damage response ⁷⁴ Show member pathways DNA damage response ⁷⁴	12.04	TP53 RB1 MYC CDKN1A
22	Cyclins and Cell Cycle Regulation ⁶⁴ Show member pathways Cell Cycle Control by BTG Proteins ⁶⁴ G1-S Phase Transition ⁶⁴	12.04	TP53 RB1 CDKN2A CDKN1A
23	Spinal cord injury ⁷⁴	11.94	TP53 RB1 MYC
24	Direct p53 effectors ⁶¹	11.94	TP53 TAP1 RB1 CDKN1A BCL2
25	Gastrin signaling pathway ⁷⁴	11.93	MYC CDKN2A CDKN1A
26	Interleukin-4 and Interleukin-13 signaling ⁶⁶	11.91	BCL2 CDKN1A MYC TP53
27	DNA damage response (only ATM dependent) ⁷⁴	11.88	TP53 MYC CDKN1A BCL2
28	Senescence and autophagy in cancer ⁷⁴	11.82	TP53 RB1 CDKN2A CDKN1A BCL2
29	Retinoblastoma gene in cancer ⁷⁴	11.78	TP53 RB1 MYC CDKN1A
30	C-MYB transcription factor network ⁶¹	11.74	MYC CDKN2A CDKN1A BCL2
31	p73 transcription factor network ⁶¹	11.73	RB1 MYC CDKN1A
32	Head and neck squamous cell carcinoma ⁷⁴	11.69	TP53 RB1 CDKN2A CDKN1A
33	AP-1 transcription factor network ⁶¹	11.68	TP53 MYC CDKN2A
34	miRNAs involved in DNA damage response ⁷⁴	11.67	TP53 MYC CDKN1A
35	E2F transcription factor network ⁶¹	11.63	RB1 MYC CDKN2A CDKN1A
36	Validated targets of C-MYC transcriptional repression ⁶¹	11.62	MYC CDKN1A BCL2
37	Regulation of retinoblastoma protein ⁶¹	11.57	RB1 CDKN2A CDKN1A
38	Prader-Willi and Angelman syndrome ⁷⁴	11.57	CDKN2A RB1 TP53 UBE3A
39	Hepatitis C and hepatocellular carcinoma ⁷⁴	11.56	TP53 MYC CDKN1A
40	Transcription_P53 signaling pathway ²²	11.47	UBE3A TP53 RB1 CDKN2A CDKN1A BCL2
41	DNA damage_ATM/ATR regulation of G1/S checkpoint ²²	11.45	TP53 MYC CDKN1A
42	Small cell lung cancer ⁷⁴	11.42	TP53 RB1 MYC FHIT CDKN1A BCL2
43	FOXM1 transcription factor network ⁶¹	11.35	RB1 MYC CDKN2A
44	Integrated cancer pathway ⁷⁴	11.34	TP53 RB1 MYC BCL2
45	Oncogene Induced Senescence ⁶⁶	11.29	TP53 RB1 CDKN2A
46	Bladder cancer ⁷⁴	11.16	TP53 RB1 MYC CDKN2A CDKN1A
47	Pathogenesis of ALS ⁶⁴	11.12	TP53 BCL2
48	C-MYC pathway ⁶¹	11.12	MYC CDKN2A
49	Unfolded protein response ⁷⁴	11.06	TP53 BCL2
50	Regulation of apoptosis by parathyroid hormone-related protein ⁷⁴	11.06	MYC BCL2

Sources

GO Terms for Suppressor of Tumorigenicity 3

Biological processes related to Suppressor of Tumorigenicity 3 according to GeneCards Suite gene sharing:

(show all 21)

#	Name	GO ID	Score	Top Affiliating Genes
1	response to xenobiotic stimulus	GO:0009410	10.14	TP53 MYC CA9 BCL2
2	negative regulation of cell population proliferation	GO:0008285	10.14	TP53 RB1 CDKN2A CDKN1A BCL2
3	regulation of cell cycle	GO:0051726	10.06	TP53 RB1 CDKN2A CDKN1A BCL2
4	neuron apoptotic process	GO:0051402	10.05	TP53 RB1 BCL2
5	cellular response to xenobiotic stimulus	GO:0071466	10.03	TP53 RB1 MYC
6	cellular senescence	GO:0090398	10	TP53 CDKN2A CDKN1A
7	cellular response to glucose starvation	GO:0042149	9.99	TP53 PLIN3 BCL2
8	negative regulation of G1/S transition of mitotic cell cycle	GO:2000134	9.95	BCL2 CDKN1A RB1
9	DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator	GO:0006978	9.9	TP53 CDKN1A
10	negative regulation of glial cell proliferation	GO:0060253	9.87	TP53 RB1
11	Ras protein signal transduction	GO:0007265	9.86	CDKN1A CDKN2A RB1 TP53
12	regulation of mitotic cell cycle	GO:0007346	9.85	CDKN1A RB1 TP53
13	response to gamma radiation	GO:0010332	9.85	TP53 MYC BCL2
14	regulation of G2/M transition of mitotic cell cycle	GO:0010389	9.76	CDKN2A CDKN1A
15	B cell lineage commitment	GO:0002326	9.76	TP53 BCL2
16	T cell lineage commitment	GO:0002360	9.67	TP53 BCL2
17	replicative senescence	GO:0090399	9.63	TP53 CDKN2A CDKN1A
18	signal transduction by p53 class mediator	GO:0072331	9.61	TP53 CDKN1A
19	negative regulation of mitotic cell cycle	GO:0045930	9.5	TP53 RB1 BCL2
20	G1/S transition of mitotic cell cycle	GO:0000082	9.5	RB1 MYC CDKN1A BCL2
21	negative regulation of cell growth	GO:0030308	9.32	TP53 RB1 CDKN2A CDKN1A BCL2

Molecular functions related to Suppressor of Tumorigenicity 3 according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	ubiquitin protein ligase binding	GO:0031625	9.85	TP53 RB1 FHIT CDKN1A BCL2
2	cyclin-dependent protein serine/threonine kinase inhibitor activity	GO:0004861	9.56	CDKN2A CDKN1A
3	disordered domain specific binding	GO:0097718	9.35	TP53 RB1 CDKN2A
4	molecular function activator activity	GO:0140677	9.1	TP53 CDKN1A CA9